Literature DB >> 12878535

Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis.

Charlene F Dailey1, Paul J Pagano, Lewis V Buchanan, Jennifer A Paquette, Joseph V Haas, John K Gibson.   

Abstract

The efficacy of linezolid, alone or in combination with rifampin, against methicillin-susceptible Staphylococcus aureus in rabbits with experimental endocarditis was investigated. Linezolid (50 or 75 mg/kg of body weight), rifampin, and linezolid (25, 50, or 75 mg/kg) plus rifampin produced statistically significant reductions in bacterial counts compared with those in untreated controls. Plasma or valvular vegetation levels of linezolid in the groups treated with the linezolid-rifampin combination were similar to those in the respective linezolid-only treatment groups. At therapeutic levels of linezolid, rifampin resistance was not observed. The results from this experimental model of endocarditis suggest that while rifampin did not provide synergy to the linezolid dosing, it did not antagonize the efficacy of linezolid.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878535      PMCID: PMC166060          DOI: 10.1128/AAC.47.8.2655-2658.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog.

Authors:  J G Slatter; L A Adams; E C Bush; K Chiba; P T Daley-Yates; K L Feenstra; S Koike; N Ozawa; G W Peng; J P Sams; M R Schuette; S Yamazaki
Journal:  Xenobiotica       Date:  2002-10       Impact factor: 1.908

2.  Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.

Authors:  H M Babcock; D J Ritchie; E Christiansen; R Starlin; R Little; S Stanley
Journal:  Clin Infect Dis       Date:  2001-04-09       Impact factor: 9.079

3.  Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.

Authors:  W Zimmerli; A F Widmer; M Blatter; R Frei; P E Ochsner
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

4.  Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.

Authors:  H F Chambers; Q Xiang; L L Chow; C Hackbarth
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Experimental bacterial endocarditis. I. Colonization of a sterile vegetation.

Authors:  D T Durack; P B Beeson
Journal:  Br J Exp Pathol       Date:  1972-02

6.  In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  L Mulazimoglu; S D Drenning; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

7.  Interaction between vancomycin and rifampin against Staphylococcus aureus.

Authors:  C Watanakunakorn; J C Guerriero
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

8.  Efficacy of linezolid in a staphylococcal endocarditis rabbit model.

Authors:  M P Oramas-Shirey; L V Buchanan; C L Dileto-Fang; C F Dailey; C W Ford; D H Batts; J K Gibson
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

9.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

10.  Staphylococcus aureus infection of dialysis shunt: absence of synergy with vancomycin and rifampin.

Authors:  R W Tofte; J Solliday; J Rotschafer; K B Crossley
Journal:  South Med J       Date:  1981-05       Impact factor: 0.954

View more
  10 in total

1.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

3.  Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.

Authors:  George Athanassopoulos; Angelos Pefanis; Vissaria Sakka; Dimitrios Iliopoulos; Despina Perrea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Infective endocarditis treated with linezolid: case report and literature review.

Authors:  E E Hill; P Herijgers; M-C Herregods; W E Peetermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

5.  Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Vien T M Le; Christine Tkaczyk; Sally Chau; Renee L Rao; Etyene Castro Dip; Eliane P Pereira-Franchi; Lily Cheng; Sally Lee; Holly Koelkebeck; Jamese J Hilliard; Xiang Qing Yu; Vivekananda Datta; Vien Nguyen; William Weiss; Laszlo Prokai; Terrence O'Day; C Kendall Stover; Bret R Sellman; Binh An Diep
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus.

Authors:  Cedric Jacqueline; Jocelyne Caillon; Olivier Grossi; Virginie Le Mabecque; Anne-Françoise Miegeville; Denis Bugnon; Eric Batard; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.

Authors:  Jordan R Smith; Juwon Yim; Seth Rice; Kyle Stamper; Razie Kebriaei; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant Staphylococcus aureus.

Authors:  Mustafa Sacar; Suzan Sacar; Nural Cevahir; Gokhan Onem; Zafer Teke; Ali Asan; Huseyin Turgut; Fahri Adali; Ilknur Kaleli; Ibrahim Susam; Yalin Tolga Yaylali; Ahmet Baltalarli
Journal:  Tex Heart Inst J       Date:  2010

Review 9.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

Review 10.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.